Table 1 Comparison of baseline clinical and pathological data of breast cancer patients
Clinical feature | Training group | Validation group | t/χ2 value | P value |
|---|---|---|---|---|
Age (year) | 49.13 ± 11.90 | 49.95 ± 11.05 | −0.009 | 0.993 |
Menstrual status (n, %) | Â | Â | 1.394 | 0.238 |
 Before | 120 (66.7) | 72 (60.0) |  |  |
 After | 60 (33.3) | 48 (40.0) |  |  |
Pathological stage (n, %) | Â | Â | 4.197 | 0.123 |
 I | 12 (6.7) | 2 (1.7) |  |  |
 II | 88 (48.9) | 53 (44.1) |  |  |
 III | 80 (44.42) | 64 (54.2) |  |  |
Molecular type (n, %) | Â | Â | 1.227 | 0.754 |
 Luminal A | 20 (11.1) | 11 (9.2) |  |  |
 Luminal B | 55 (30.6) | 36 (30.0) |  |  |
 HER2 overexpression | 43 (23.9) | 31 (25.8) |  |  |
 Triple-negative | 62 (34.4) | 42 (35.0) |  |  |